Adaptimmune Therapeutics plc (ADAP)

Oncology Corporate Profile

HQ Location

91 Park Drive, Milton Park
Abingdon
Oxfordshire, OX14 4RY

Company Description

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the body's own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune's lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen.

Website: http://www.adaptimmune.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
NY-ESO TCRT-cell receptorMelanomaIGlaxoSmithKline
NY-ESO TCRT-cell receptorMultiple MyelomaIGlaxoSmithKline
NY-ESO TCRT-cell receptorNon Small Cell Lung Cancer (NSCLC)IGlaxoSmithKline
MAGE-A10 TCRT-cell receptorNon Small Cell Lung Cancer (NSCLC)I
NY-ESO TCRT-cell receptorOvarian cancerIGlaxoSmithKline
MAGE-A10 TCRT-cell receptorBladder cancerPreclinical
MAGE-A10 TCRT-cell receptorHead & Neck cancerPreclinical
AFP TCRT-cell receptorHepatocellular carcinoma (HCC)Preclinical
MAGE-A10 TCRT-cell receptorMelanomaPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.adaptimmune.com/

Recent News Headlines

Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit

3/27/2017 08:03 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 27, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’ s Chief Executive Officer, ...

Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

3/27/2017 03:03 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, UK, March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune") (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing ...

Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

3/27/2017 03:02 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, UK, March 27, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering ...

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

3/22/2017 02:00 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced ...

Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

3/22/2017 01:05 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 22, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 ...

Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

3/21/2017 11:04 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, 2017-03-22 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer ...

Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

3/21/2017 08:05 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 21, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary ...

Adaptimmune Broadens Executive Team

3/15/2017 11:03 am

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 15, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it has broadened its executive team with the appointment ...

Adaptimmune Broadens Executive Team

3/15/2017 11:03 am

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 15, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has broadened ...

Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results

3/13/2017 11:03 am

[GlobeNewswire] - –Opened two new INDs for wholly-owned SPEAR ® T-cell therapies; Company now has four open INDs in 11 indications–. –Received orphan designation, PRIME regulatory support and Breakthrough Therapy designation ...

Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results

3/13/2017 11:03 am

[GlobeNewswire] - - Opened two new INDs for wholly-owned SPEAR® T-cell therapies; Company now has four open INDs in 11 indications - - Received orphan designation, PRIME regulatory support and Breakthrough Therapy designation ...

Adaptimmune to Report Fourth Quarter and Full Year 2016 Financial Results on March 13, 2017

3/8/2017 01:00 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 08, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, will announce financial results for the fourth quarter and full year ...

Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference

3/2/2017 01:00 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 02, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’ s Chief Executive Officer, ...

Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in Philadelphia

3/1/2017 01:03 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, March 01, 2017-- Adaptimmune Therapeutics plc., a leader in T-cell therapy to treat cancer, today announced it will host a ribbon cutting ceremony this morning ...

Adaptimmune to Participate in Upcoming Investor Conference

2/9/2017 07:00 pm

[GlobeNewswire] - PHILADELPHIA and OXFORD, U.K., Feb. 09, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Adaptimmune’ s Chief Financial Officer, will ...